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Peroxisome proliferator-activated receptors belong to the superfamily of ligand-dependent nuclear receptor transcription factors,
whichincludethreesubtypes:PPAR-α,β/δ,andγ.PP AR -δ,playimportantrolesintheregulationofcellgrowthanddiﬀerentiation
as well as tissue wound and repair. Emerging evidence has also demonstrated that PPAR-δ is implicated in lipids and glucose
metabolism. Most recently, the direct eﬀects of PPAR-δ on cardiovascular processes such as endothelial function and angiogenesis
have also been investigated. Therefore, it is suggested that PPAR-δ may have critical roles in cardiovascular pathophysiology and is
a potential target for therapeutic intervention of cardiovascular disorders such as atherosclerosis.
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1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
members of nuclear receptor/ligand-activated transcription
factors superfamily. PPAR subfamily consists of 3 subtypes:
PPAR-α,- β/δ,a n d- γ. PPARs form heterodimers with a
retinoid X receptor (RXR) and bind to speciﬁc PPAR-
responsive elements (PPREs) to regulate target gene expres-
sion. In the absence of speciﬁc ligands, the PPAR-RXR
heterodimer forms repressive complex with corepressors
and histone deacetylases. Upon ligand binding, the receptor
undergoes conformational changes that cause the dissoci-
ation of repressors, the recruitment of coactivators, and
the activation of gene transcription [1]. Recently, extensive
studies have been performed to characterize the biological
and pathophysiological roles of PPAR-α and -γ, which are
pharmacological targets of the clinical interventions for
dyslipidemia and type 2 diabetes, respectively. Fibrates class
of lipid-lowering drugs such as fenoﬁbrate and gemﬁbrozil
are agonists for PPAR-α. Thiazolidinedione class of insulin
sensitizers including troglitazone (Rezulin), rosiglitazone
(Avandia), and pioglitazone (Actos) are speciﬁc ligands for
PPAR-γ [2]. PPAR-α, primarily expressed in liver, muscles,
heart, and kidney, plays a key role in fatty acid catabolism
such as β-oxidation. PPAR-γ is highly expressed in fat,
controlsadipogenesis, and regulatesinsulin action. However,
relatively little has been known with regards to the function
of PPAR-δ, the only subtype of PPARs that is not a target
of current drug. Newly developed synthetic ligands and
genetically modiﬁed mouse models for PPAR-δ have rapidly
advanced our understanding of the important roles of
PPAR-δ in tissue development, repair, inﬂammation, and
metabolism[3–7].Mostrecently,thedirecteﬀectsofPPAR-δ
on cardiovascular processes such as endothelial function and
angiogenesis have also been investigated. In this review, we
will focus on the recent advancements regarding the roles of
PPAR-δ in vascular pathophysiological processes.
2. MATERIALS AND METHODS
2.1. Geneandprotein
PPAR-δ,alsoknownasnuclearhormonereceptor1(NUC1),
PPAR-β, or NR1C2, was ﬁrst cloned in 1992 [8, 9]. The
PPAR-δ gene is mapped to human chromosome 6p21.2-
p21.1 and has 11 exons, spanning 35 kilobase-pair [10].
Like other PPARs, PPAR-δ protein has a modular structure
consisted of 5 regions: an N-terminal region (A/B), a DNA-
binding domain (C), a ﬂexible hinge region (D), ligand-
binding domain (E), and a C-terminal region (F). X-
ray crystallographic study revealed that PPAR-δ has an
exceptionally large ligand binding pocket, which maybe
related to the promiscuous accommodation of a large range
of mostly amphipathic ligands [11, 12].2 PPAR Research
2.2. Endogenousandsyntheticligands
Several 14- to 18-carbon saturated fatty acids and 16- to 20-
carbon polyunsaturated fatty acids can bind PPAR-δ [13–
15]. Naturally occurring or synthetic eicosanoids such as
prostaglandin A1 and carbaprostacyclin have been shown to
bind and activate PPAR-δ [16]. Very low-density lipoprotein
(VLDL) derived has also been demonstrated to activate the
PPAR-δ target genes in a receptor-dependent manner [17].
Since these agonists activate PPAR-δ all with aﬃnities at
molar range, it raises a question as to whether these are
bona ﬁde physiological ligands for PPAR-δ.H o w e v e r ,m a n y
of the above-mentioned agonists under the physiological or
pathological conditions are either released by the vessels,
such as PGI2, or being exposed to vascular endothelium,
such as VLDL. It would be intriguing to examine whether
PPAR-δ in the vessel wall is activated in vivo. In addition, it
was recently shown that retinoic acid, a ligand for retinoic
acid receptor, also can activate the PPAR-δ with nanomolar
aﬃnity without aﬀecting the other two subtypes of PPARs
[18]. This ﬁnding expanded our understanding of the
mechanisms of PPAR-δ activation.
Recently, several synthetic ligands have been reported to
selectively activate PPAR-δ. The PPAR-δ agonists reported to
date were discovered using several strategies: GW501516 and
GW-0742 (GlaxoSmithKline) were optimized from a library
of hydrophobic carboxylates [19]; L165461 (Merck) was
derived from an in silico approach [20]. These derivatives of
phenoxyacetic acid are the highly selective PPAR-δ ligands
with a nanomolar aﬃnity and 1000-fold selectivity over
PPAR-α and -γ. Other PPAR-δ agonists including KD3010
(Kalypsys) and MBX-8025 (Metabolex) are currently in
clinical development. On the other hand, the development
of these speciﬁc agonists has greatly aided the investigation
in the biological functions of PPAR-δ. A selective antagonist
for PPAR-δ, GSK0660, has also been recently demonstrated
as it by itself exhibits inverse agonist activity and competes
with agonist in a cellular context [21]( Table 1).
2.3. Effectsonthevesselwall
Although nearly ubiquitously expressed with highest levels
in placenta, skeletal muscles, and adipose tissue, PPARδ is
also expressed in the vascular cells including endothelial cells
[22], smooth muscle cells, and macrophages. Particularly, a
number of studies during the past 2 years have demonstrated
that PPAR-δ plays direct roles in various basic vascular
processes such as apoptosis, survival, angiogenesis, and
inﬂammation.
2.4. Endothelialapoptosis
Vascular endothelium, when unperturbed, is considered to
provide a relatively nonadhesive and nonthrombotic inter-
face. This characteristic is likely essential to physiological
homeostasis. However, endothelial cells (ECs) can undergo
apoptosis in vitro in response to a variety of pathophys-
iological conditions including hypoxia, proinﬂammatory
cytokines, bacterial endotoxins, and atherogenic risk factors
suchashomocysteineandlipoproteins[23,24].ECapoptosis
has been implicated in numerous pathophysiological pro-
cesses, such as angiogenesis, thrombosis, and atherosclerosis.
On the other hand, ECs produce a plethora of bioactive
molecules to maintain vascular homeostasis. Among those,
prostacyclin (PGI2) protects ECs from apoptosis. Although
PPAR-δ has been previously documented to protect against
the hypertonicity-induced apoptosis in renal cells [25]a n d
the growth factor deprivation- or anoikis-induced apoptosis
in keratinocytes [6], its role in vascular cells has been
recently demonstrated. Liou et al. showed that PGI2 pro-
tects ECs from H2O2-induced apoptosis via the action of
PPAR-δ. By inducing the expression of its target gene 14-
3-3alpha, PPAR-δ prevents Bad-triggered apoptosis [26].
Treatment with L165041 or overexpression of PPAR-δ also
has a similar eﬀect. In addition, small interfering RNA-
mediatedknockdownofPPAR-δ abrogatedtheantiapoptotic
eﬀect, suggesting that the antiapoptotic role of PPAR-δ
appearedtobespeciﬁcforanddependentontheendogenous
PPAR-δ receptor. Interestingly, gene expression of 14-3-
3epsilon was also induced by PPAR-δ through a PPRE-
independentmechanismandaninteractionbetweenPPAR-δ
and CCAAT/enhancer binding protein (C/EBP) [27].
2.5. Endothelialactivation
When exposed to proinﬂammatory stimuli such as tumor
necrosis factor (TNF) or lipopolysaccharide (LPS), normally
quiescent endothelium undergoes a phenotypic change,
which is characterized by induction of proinﬂammatory and
procoagulant factors such as adhesion molecules and tissue
factor. Such a phenotypic conversion, referred to as EC acti-
vation, is implicated in a number of proinﬂammatory dis-
eases including atherosclerosis and thrombosis [28]. PPAR-α
and -γ have been previously shown to suppress EC expres-
sion of proinﬂammatory adhesion molecules such as inter-
cellular adhesion molecule-1 (ICAM-1), vascular adhesion
molecule-1 (VCAM-1), E-selectin, monocyte chemoattac-
tant protein-1 (MCP-1), and ensuing recruitment of leuko-
cytes [22, 29–32]. However, there has also been evidence that
suggests a proinﬂammatory role of PPAR-α or -γ [33, 34].
Recent studies suggested that PPAR-δ also plays a role in
inﬂammatoryprocessesandatherosclerosis.Inmacrophages,
the PPAR-δ agonist GW0742 inhibited lipopolysaccharide
(LPS)-inducedexpressionofproinﬂammatorygenes,suchas
cyclooxygenase (COX)-2 and inducible nitric oxide synthase
(iNOS) [35]. GW0742 reduced atherosclerotic lesions and
decreased the expression of MCP-1 and ICAM-1 in the aorta
of LDLR
−/− mice [36, 37]. Given the beneﬁcial eﬀects of
PPAR-δ agonists on lipid proﬁles, it is likely that PPAR-
δ agonists may inhibit endothelial activation by improving
dyslipidemia. A direct anti-inﬂammatory eﬀect was also
demonstrated. In EAhy926 cells, Rival et al. found that L-
165041, at high a concentration up to 100μM, inhibited
TNF-α-induced VCAM-1 and MCP-1 expressions [38]. In
primary culture of human umbilical vein ECs (HUVECs),
speciﬁc agonists GW0742 and GW501516 inhibited the
TNF-α- or interleukin-1β-induced expression of adhesionNanping Wang 3
Table 1: Ligands for PPAR-δ.
Ligands Nature Aﬃnity Clinical status
Natural agonists
Linoleic acid Dietary fatty acid μM
Oleic acid Dietary fatty acid μM
Arachidonic acid Dietary fatty acid μM
Eicosapentaenoic acid Dietary fatty acid μM
Docosahexaenoic acid Dietary fatty acid μM
Prostaglandin A1 Endogenous prostaglandin μM
Synthetic agonists
Carbaprostacyclin Synthetic stable PGI2 analogue μM
Iliprost Prostacyclin analogue μM
Compound F Phenoxyacetic acid derivative nM
L165,041 Phenoxyacetic acid derivative nM
GW501516 Phenoxyacetic acid derivative nM
GW0742 Phenoxyacetic acid derivative nM
KD2010 not disclosed nM Phase I
MBX-8025 not disclosed nM Phase II
Synthetic dual agonists
Compound 23 Dual agonist for γ and δ nM
Synthetic antagonist
GSK0660 Antagonist for δ nM
molecules and the monocyte adhesion to ECs. PPAR-δ ago-
nist induced the gene expression of antioxidative enzymes,
such as superoxide dismutase-1, catalase, and thioredoxin,
and it decreased reactive oxygen species production in
ECs. Unexpectedly, the anti-inﬂammatory eﬀect not only
persisted but it also was further enhanced after the decrease
of PPAR-δ expression by siRNA knockdown [39]. Given
the evidence that the ligand binding caused the dissociation
of the transcription repressor BCL-6 from PPAR-δ and
the subsequent association of BCL-6 with the VCAM-1
promoter region, this seemingly paradoxical result could be
plausibly interpreted with the previously proposed PPAR-
δ/Bcl-6 interaction action mode: the synthetic ligand binds
to PPAR-δ and recruits the coactivators to replace the
corepressorssuchasBcl-6. Thereleasedcorepressorsrelocate
torepressthetranscriptionofproinﬂammatorygenessuchas
VCAM-1 and E-selectin and thus contribute to the vascular
protection.
Ghosh et al. recently showed that the metabolism of
endocannabinoids by the endothelial COX-2 coupled to
the prostacyclin synthase activates PPAR-δ,w h i c hn e g a t i v e l y
regulates the expression of tissue factor (TF), the primary
initiator of blood coagulation [40]. As COX-2 inhibitors
suppressedPPAR-δ activityandinducedTFexpression,these
resultsmayhelpexplainingtheprothromboticadverseeﬀects
of the cox-2 inhibitors rofecoxib and valdecoxib [41].
2.6. Angiogenesis
Angiogenesis is referred to the formation of new capillaries
from the existing blood vessels. Physiological angiogenesis
is involved in wound healing and aerobic exercise, whereas
pathological or therapeutic angiogenesis is implicated in
cardiovascular diseases, diabetic complications, inﬂamma-
tory diseases, and cancers [42]. Recent studies have also
linked metabolic homeostasis to angiogenesis and further
interrogate the potential eﬀects of PPARs on the angiogenic
process [43, 44]. An earlier study demonstrated that the
PPAR-δ agonist GW501516 dose-dependently stimulates
HUVEC proliferation with increased mRNA expression of
vascular endothelial growth factor α and its receptor ﬂt-1
[45]. Later, GW501516 was shown to promote endothelial
t u b ef o r m a t i o no na ne x t r a c e l l u l a rm a t r i g e l ,E Co u t g r o w t h
in a murine aortic ring model, and increased angiogenesis
in the implanted matrigel plug assay in vivo through a
PPAR-δ- and VEGF-dependent manner [22]. Most recently,
Gaudel et al. found that treatment with GW0742 or muscle-
speciﬁc overexpression of PPAR-δ promoted angiogenesis in
mouse skeletal muscle [46]. Besides, arising from sprouts
on existing vessels, vessels also arise from endothelial pro-
genitorcells (EPCs), a process referred to as vasculogenesis
[47]. Culminating evidence further suggests that circulating
EPCs is capable of stimulating angiogenesis [48]. A recent
study showed that the proangiogenic eﬀects of human EPCs
are in part dependent on the biosynthesis and release of
PGI2, and subsequent activation of PPAR-δ [48, 49]. Fur-
thermore, functional genomic approach provided evidence
that silencing of PPAR-δ in the tumor microenvironment
impairs angiogenesis and tumor growth, identifying PPAR-
δ as one of a few hub nodes in the angiogenic network
[49, 50]. Up-to-date results have been largely consistent
and pointed toward a proangiogenic activity of PPAR-δ.
In corroboration with this, M¨ uller-Br¨ usselbach et al. found
that the growth of syngeneic PPAR-δ wild-type tumors was4 PPAR Research
impaired in PPAR-δ−/− mice, concomitant with a reduced
blood ﬂow and hyperplastic vascular structures, suggesting
that PPAR-δ maybe required in tumor ECs for the formation
of functionally mature vessels [51]. Nevertheless, a full
understanding of the speciﬁc roles of PPAR-δ in speciﬁc
scenarios of angiogenesis will be imperative for a safe and
rational therapeutic strategy.
2.7. Smoothmusclecells
PPAR-δ is expressed in SMCs and is induced in response
to platelet-derived growth factor (PDGF) in SMCs,
which involved the phosphatidylinositol 3-kinase/Akt
signaling pathway. Initial study using overexpression showed
that PPAR-δ increased SMC proliferation, indicating a
proliferation-promoting eﬀect in SMCs [52]. However,
L-165041, a selective PPAR-δ agonist, inhibited SMC
proliferation and migration via inhibition of the PDGF-
induced expression of cyclin D1 and cyclin-dependent
kinase (CDK) 4 and cell cycle progression [53]. In SMCs,
GW501516 increased the expression of transforming
growth factor-β1( T G F - β1) and the eﬀect seemed to
depend on endogenous PPAR-δ. Subsequently, TGF-β1
was likely responsible for suppression of the IL1β-induced
expression of MCP-1 and proliferation of SMCs [54]. In rats,
administration of L-165041 decreased neointima formation
in balloon-injured carotid arteries [53]. Thus, synthetic
PPAR-δ agonists appear to have antiproliferative and anti-
inﬂammatory properties in SMCs. This is consistent with
previous reports that adenovirus-mediated gene transfer
of prostacyclin synthase, which produces the endogenous
PPAR-δ ligand PGI2, inhibited SMCs proliferation and
intimal hyperplasia [55–57].
2.8. Macrophages
Macrophage inﬁltration in vessel wall is known to play
important role in atherogenesis. PPAR-δ is expressed in
macrophages. During past years, the role of PPAR-δ in
macrophage biology has been extensively studied. How-
ever, existing results still remain controversial. Oliver Jr.
et al. showed that GW501516 in a human monocytic cell
line increased the expression of ATP-binding cassette A1
(ABCA1) and Apo AI-mediated cholesterol eﬄux [58].
However, Vosper et al. found that a diﬀerent PPAR-δ
agonist, compound F, increased lipid accumulation in both
human primary macrophages and THP-1 cells. Compound
F induced the expression of genes involved in lipid uptake
and storage such as class A and B scavenger receptors
(SRA and CD36) but repressed key genes involved in lipid
metabolism and eﬄux such as Apo E and cholesterol 27-
hydroxylase [59]. In mouse macrophages, neither genetic
loss of PPAR-δ nor treatment with the PPAR-δ agonists
GW501516 or GW0742 signiﬁcantly inﬂuenced cholesterol
eﬄux or accumulation [36, 60]. Beside the eﬀects on lipid
traﬃcking, PPARδ agonists have a potent anti-inﬂammatory
eﬀect in macrophages. Welch et al. ﬁrst demonstrated
that, in mouse peritoneal macrophages, PPAR-δ agonist
GW0742 inhibited LPS-induced expression of COX-2 and
iNOS [32, 35]. Recently, Barish et al. found that GW501516
in mouse macrophages suppressed the gene induction of
MCP-1, -3, -5 by IL-1, interferon-γ (IFN-γ), and phorbol
ester. The agonist treatment also inhibited transendothelial
migration of THP-1 cells [61]. The anti-inﬂammatory eﬀects
of the agonist was lost in the receptor-deﬁcient macrophages
[60]. However, in other cell types such as epithelial cells,
eosinophils, neutrophils, and lymphocytes, the PPAR-δ
agonist was ineﬀective in inhibiting inﬂammatory processes,
indicating that the eﬀect is cell-type-speciﬁc [62].
2.9. Atherosclerosis
To date, several studies have been reported regarding the
roles of PPAR-δ in atherosclerosis in diﬀerent mouse models
with diﬀerent approaches. Lee et al. transplanted PPAR-
δ-null bone marrow progenitor cells into LDL receptor-
null (LDLR
−/−) mice. Unexpectedly, the adoptive transfer of
PPAR-δ-null macrophages led to a less severe atherosclero-
sis, suggesting that endogenous PPAR-δ maybe proathero-
genic. Although overexpression or deletion of PPAR-δ in
macrophages suggested that PPAR-δ is proinﬂammatory,
the agonist GW501516 decreased MCP-1, seemingly having
an opposite eﬀect [60]. To reconcile this contradiction,
they postulated an unconventional ligand-dependent tran-
scriptional mechanism, which switches PPAR-δ between a
“proinﬂammatory” and “anti-inﬂammatory”: in the absence
of ligand, PPAR-δ sequesters a transcriptional repressor of
inﬂammatory responses such as Bcl-6, permitting induction
of proinﬂammatory genes; in the presence of ligand, PPAR-
δ releases the repressor, which is then free to exert its
anti-inﬂammatory eﬀects. Following this loss-of-function
approach, two independent studies examined the eﬀect of
the PPAR-δ agonist GW0742 on atherogenesis in high fat-
and cholesterol-fed LDLR
−/− mice and yielded divergent
results. In the ﬁrst study, Li et al. found that GW7842
decreased gene expression of proinﬂammatory cytokines
and adhesion molecules within atherosclerotic lesions but
failed to alter the progression of atherosclerosis after 14
weeks of treatment (5mg−1kg−1day
−1). In another one,
Graham et al. used female LDLR
−/− mice fed with a diet
that induced moderate levels of hypercholesterolemia and
observed that GW0742 reduced the lesion size at a higher
dose (60mg−1kg−1 day
−1)a f t e r1 0w e e k so ft r e a t m e n t[ 37].
Discrepancy between these two studies may be caused
by diﬀerences in the levels of hypercholesterolemia and
diﬀerent drug doses used. However, the anti-inﬂammatory
eﬀect was generally consistent in both studies, regardless
the diﬀerent eﬀects on the lesion sizes. It is likely that the
anti-inﬂammatory properties of the PPAR-δ agonists on
the vessel wall per se are not suﬃcient to attenuate the
progression of atherosclerotic lesions if it is not corroborated
byaneﬃcientimprovementofmetabolicabnormalities.This
notion is supported by the data from recently published
results. Most recently, GW501516, which has a potent
lipid-modifying capacity, has also been demonstrated to
have a clear antiatherosclerotic property in apoE
−/− mice.
Barish et al. showed that GW501516 signiﬁcantly reduced
atherosclerotic lesions with an increase in HDL level andNanping Wang 5
a reduced expression of chemokines in the aorta and in
macrophages [61]. Furthermore, in a model of angiotensin
II-accelerated atherosclerosis (LDLR
−/− mice), Takata et
al. conﬁrmed the atheroprotective eﬀect of GW0742 [63].
After 4 weeks of treatment, GW0742 at both doses (1
and 10mg−1kg−1day
−1) signiﬁcantly inhibited the Ang II
induction of atherosclerosis without altering blood pressure.
This beneﬁcial eﬀect was likely mediated via the potent anti-
inﬂammatory property since GW0742 increased vascular
expression of Bcl-6, the regulators of G protein-coupled
signaling (RGS4 and 5) in the artery and suppressed Ang
II-induced activation of p38 and ERK in macrophages.
However,themetaboliceﬀectofGW0742mayalsohavecon-
tributed to the atheroprotective outcome because GW0742
signiﬁcantly reduced plasma levels of insulin, glucose, leptin,
and decreased triglycerides [63]. Overall, studies in mouse
modelssuggestthatPPAR-δ mayhaveanattractivetherapeu-
tic target for the treatment of atherosclerosis.
2.10. Cardiovascularriskfactors
In addition to the direct eﬀects on the vessel wall, PPAR-δ
also has profound eﬀects on various metabolic parameters
associated with cardiovascular diseases such as obesity,
dyslipidemia, and insulin resistance.
2.11. Obesity
PPAR-δ deﬁciency causes embryonic lethality due to a
placental defect. Some surviving PPAR-δ null mice had
reduced fat mass [3], indicating a role of PPAR-δ in adipo-
genesis. Transgenic mice speciﬁcally expressing VP16-PPAR-
δ, a constitutively active receptor, in adipose tissue had a
reduced body weight, fatmass, and lower levelsof circulating
free fatty acids and triglycerides [64]. These animals were
less susceptible to high-fat diet-induced obesity. In contrast,
PPAR-δ null mice were more prone to weight gain on a
high-fatdiet.Similarly,GW501516ameliorateddiet-induced
obesity [65]. It has been known that PPAR-δ activates genes
involved in fatty acid oxidation and energy dissipation, such
ascarnitinepalmitoyltransferase1(CPT1),acyl-CoAoxidase
(AOX), and long chain acyl-CoA dehydrogenase (LCAD),
uncoupling proteins. In addition to the direct eﬀects on
obesity, PPAR-δ agonists may also have regulatory eﬀects on
adipokine proﬁle. For example, administration of L-165041
in rats increased the expression of visfatin and adiponectin,
which are known to improve insulin sensitivity and are
vasoprotective, but decreased the production of resistin in
visceral adipose tissue [66].
2.12. Dyslipidemia
Increased levels of LDL and triglycerides and decreased HDL
in plasma are independent risk factors for atherosclerosis
and associated with metabolic syndrome as well. Recent
studies have demonstrated that activation of PPAR-δ may
modify lipid proﬁle in animal models as well as in human.
Oliver Jr. et al. ﬁrst reported that GW501516 signiﬁcantly
improved dyslipidemia in obese primates with an increase
in HDL and a decrease in LDL cholesterol and triglycerides
[58]. The beneﬁcial eﬀect of GW0742 and L-165041 on
HDL level was also observed in obese and nonobese mice
[67, 68]. In addition to enhancing fatty acid oxidation in
muscles, PPAR-δ agonists upregulated expression of ABCA1
in several types of cells, which may lead to an increase in
HDL and cholesterol reverse transport. In intestinal cells,
it also inhibited gene expression of Niemann-Pick C1-
like 1, the key molecule for cholesterol absorption [67].
However, the precise mechanisms underlying these lipid-
modifying eﬀects still remain to be elucidated. In a small
number of healthy human volunteers, GW501516 has been
reported to increase HDL cholesterol level and improved the
triglycerides clearance [69].
2.13. Insulinresistanceandglucosehomeostasis
It has been previously known that, in obese primates,
GW501516 declined fasting insulin level [58]. GW501516
treated ob/ob mice also showed a signiﬁcantly improved
glucose tolerance and with a lower postprandial levels of
plasma glucose and insulin [65]. In cultured myotubes,
PPAR-δ agonists were found to directly stimulate glu-
cose uptake independent of insulin action. The agonist-
s t i m u l a t e dg l u c o s eu p t a k ei nm y o t u b e sa p p e a r e dt or e q u i r e
AMP-activated protein kinase (AMPK) but not PPAR-δ [70,
71]. However, GW501516 had no acute eﬀect on glucose
transport in rat skeletal muscles [72]. Recently, Lee et
al. showed that PPAR-δ−/− mice were glucose intolerant.
Euglycemic hyperinsulinemic clamp experiments showed
that GW501516 improved insulin sensitivity in multiple
tissues including hepatic and peripheral tissues. The agonist
suppresses hepatic glucose output and increases glucose
disposal [73]. Gene array analysis suggested that PPAR-δ
might ameliorate hyperglycemia by increasing glucose ﬂux
through the pentose phosphate pathway, which is known
to enhance de novo fatty acid synthesis. Thus, it could be
a concern whether PPAR-δ improves hyperglycemia at the
costofexacerbationofhepatosteatosis,aproblemcommonly
associated with metabolic syndrome and diabetes. However,
recent studies demonstrated that PPAR-δ also had a ben-
eﬁcial eﬀect on hepatosteatosis. In a diet-induced mouse
model of nonalcoholic steaohepatitis, GW501516 reduced
triglycerides accumulation in the livers. In a most recent
study, it was demonstrated that PPAR-δ suppressed hepatic
lipogenesis via the induction of insulin-induced gene-1
(insig-1) and the inhibition of lipogenic sterol-regulatory
element binding prortein-1 (SREBP-1) activation. In obese
diabetic mice, hepatic overexpression of PPAR-δ ameliorated
hepatosteatosis [74]. Since Insig-1 is a critical regulator of
lipid homeostasis, identiﬁcation of the insig-1 as a target
gene of PPAR-δ may also facilitate our understanding of the
profound eﬀects of PPAR-δ activation on adipogenesis and
lipid metabolism [75, 76]. Recently, in a double-blind and
randomized study, PPAR-δ agonist (10mg o.d. GW501516)
was given to a small number of healthy overweight subjects.
The results showed that treatment with GW501516 for 2
weeks signiﬁcantly reduced liver fat content by 20% without
increasing oxidative stress [77].6 PPAR Research
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Figure 1: Activation of PPAR-δ may have profound eﬀects on vascular homeostasis and coronary artery diseases. These include both the
direct actions in the vessel wall and the indirect eﬀects on multiple cardiovascular risk factors. PPAR-δ gene polymorphisms are also linked
to cardiovascular diseases.
2.14. Genepolymorphisms
Skogsberg et al. initially described 4 polymorphisms:
−409C/T (in the promoter region), +73C/T (exon 1),
+255A/G (exon 3), and +294T/C (exon 4). The +294T/C
polymorphism showed a signiﬁcant association with a
metabolic trait. The homozygotes for the C allele had a
higher plasma LDL and a tendency toward higher risk
o fC H Dc o m p a r e dw i t hh o m o z y g o u sc a r r i e r so ft h eT -
allele [78, 79]. In addition, there is a highly signiﬁcant
association between the rare C allele and lower plasma
HDL concentrations in the female patients with mixed
hyperlipidemia. Associations were also found for the C-allele
with coronary heart disease and body mass index (BMI)
[80, 81]. Chen et al. also demonstrated that, in “lipoprotein
and coronary atherosclerosis study” (LCAS) subjects, the
PPAR-δ SNPswerestronglyassociatedwiththedyslipidemia,
the responses to statin, and the atherosclerotic lesions [82].
V¨ anttinen et al. investigated the eﬀects of the PPAR-δ gene
SNPs on tissue glucose uptake and suggested that the SNPs
regulate insulin sensitivity primarily in skeletal muscles [83].
ThePPAR-δ SNPsweregenotypedintypeIIdiabetessubjects
and normal control. Although no signiﬁcant association was
detected with the risk of type II diabetes, several SNPs were
associated with fasting plasma glucose and BMI [84]. In
addition, the association has been found between the PPAR-
δ SNPs and metabolic syndrome, and the association was
inﬂuenced by dietary fat intake [85].
3. CONCLUSIONS
During the last few years, rapid progress has been made
with regards to the roles of PPAR-δ in vascular biology.
Emerging evidence supports the notion that activation of
PPAR-δ may have profound eﬀects on vascular homeostasis
and coronary artery diseases. These include both the direct
actions in the vessel wall and the beneﬁcial eﬀects on
central metabolic pathways (Figure 1). Importantly, PPAR-
δ agonists have an unprecedented role in raising HDL
level in animals. In addition to a previously reported
function of PPAR-δ in increasing oxidative muscle ﬁbers
and running endurance, a most recent study revealed that
AMPK and PPAR-δ pathways have synergistic eﬀects in
terms of exercise-enhancing capacity [86]. The outcome
of currently ongoing clinical trial is awaited to prove its
clinical eﬃcacy in the treatment of dyslipidemia. Despite
the studies in rodent models point to a vascular-protective
eﬀectforPPAR-δ agonists,theireﬃcaciesinhumancoronaryNanping Wang 7
artery diseases remain to be clariﬁed. With regards to the
eﬀects of PPAR-δ on tumor angiogenesis and the unsettled
role in carcinogenesis, safety issues also call for attention
[87, 88]. Clearly, further studies are warranted to explore the
roles of PPAR-δ in cardiovascular pathophysiology and to
exploit this lipid-sensing receptor as a therapeutic target for
metabolic syndrome and its cardiovascular complications.
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